CMS certification 054009
Resnick Neuropsychiatric Hospital at UCLA
150 Medical Plaza-Rm-4230c, Los Angeles, CA 90095
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $13.7M
- 2020 $10.9M
- 2021 $12.4M
- 2022 $7.9M
- 2023 $13.2M
- 2024 $12.8M
- 2025 $7.4M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $518,041 | 12 |
| Space rental and facility fees | $124,291 | 16 |
| Consulting fees | $5,208 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Abbvie INC. | $1.6M | 46 |
| Janssen Research & Development, LLC | $1.5M | 108 |
| Genentech, Inc. | $794,991 | 13 |
| Gilead Sciences, Inc. | $773,689 | 35 |
| Regeneron Pharmaceuticals, Inc. | $773,408 | 67 |
| Stemline Therapeutics Inc. | $424,871 | 112 |
| Kite Pharma, Inc. | $397,233 | 4 |
| Actelion Pharmaceuticals US, Inc. | $390,767 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib and Venetoclax in patients with previously untreated follicular Lymphoma ABBVIE INC. · NCT04450173 | $972,823 |
| DLBCL Salvage SD PD or Consolidation PR post Induction Therapy 1L DLBCL in Elderly Frail Genentech, Inc. | $573,328 |
| A PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, I… Regeneron Pharmaceuticals, Inc. · NCT06149286 | $451,076 |
| Phase 2 US study in persons who inject drug (PWID) US Dosage: Single Gilead Sciences, Inc. | $404,559 |
| Elucidating Resistance Mechanisms in Alpha Particle-Radiotherapy to Overcome Aggressive Prostate Cancer Janssen Research & Development, LLC | $350,000 |
| A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for H… Gilead Sciences, Inc. | $274,935 |
| STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WIT… Stemline Therapeutics Inc. | $261,779 |
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) Kite Pharma, Inc. | $217,025 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
Common questions about Resnick Neuropsychiatric Hospital at UCLA
Does Resnick Neuropsychiatric Hospital at UCLA have an emergency room?
Yes. CMS lists emergency services at Resnick Neuropsychiatric Hospital at UCLA.
Does Resnick Neuropsychiatric Hospital at UCLA receive money from drug and device companies?
Drug and device makers reported $7.4M in payments to Resnick Neuropsychiatric Hospital at UCLA for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.